DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
1999
10.3K+
Last FY Revenue $4.0B
Last FY EBITDA $946M
$25.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, DexCom reported revenue of $4.0B and EBITDA of $946M.
DexCom expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See DexCom valuation multiples based on analyst estimates| NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|
| Revenue | XXX | $4.0B | XXX | XXX | XXX |
| Gross Profit | XXX | $2.4B | XXX | XXX | XXX |
| Gross Margin | XXX | 60% | XXX | XXX | XXX |
| EBITDA | XXX | $946M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 23% | XXX | XXX | XXX |
| EBIT | XXX | $600M | XXX | XXX | XXX |
| EBIT Margin | XXX | 15% | XXX | XXX | XXX |
| Net Profit | XXX | $576M | XXX | XXX | XXX |
| Net Margin | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | $1.8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
DexCom has current market cap of $26.0B, and EV of $25.2B.
As of January 5, 2026, DexCom's stock price is $67.
See DexCom trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.2B | $26.0B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialDexCom's trades at 6.2x EV/Revenue multiple, and 26.7x EV/EBITDA.
See valuation multiples for DexCom and 15K+ public compsAs of January 5, 2026, DexCom has market cap of $26.0B and EV of $25.2B.
Equity research analysts estimate DexCom's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DexCom's P/E ratio is not available.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26.0B | XXX | $26.0B | XXX | XXX | XXX |
| EV (current) | $25.2B | XXX | $25.2B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 26.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 42.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 45.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 40.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDexCom's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
DexCom's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DexCom's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DexCom and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DexCom acquired XXX companies to date.
Last acquisition by DexCom was XXXXXXXX, XXXXX XXXXX XXXXXX . DexCom acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was DexCom founded? | DexCom was founded in 1999. |
| Where is DexCom headquartered? | DexCom is headquartered in United States of America. |
| How many employees does DexCom have? | As of today, DexCom has 10.3K+ employees. |
| Who is the CEO of DexCom? | DexCom's CEO is Mr. Kevin R. Sayer, C.P.A.. |
| Is DexCom publicy listed? | Yes, DexCom is a public company listed on NAS. |
| What is the stock symbol of DexCom? | DexCom trades under DXCM ticker. |
| When did DexCom go public? | DexCom went public in 2005. |
| Who are competitors of DexCom? | Similar companies to DexCom include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of DexCom? | DexCom's current market cap is $26.0B |
| Is DexCom profitable? | Yes, DexCom is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.